Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 2
1985 4
1986 5
1987 7
1988 3
1989 2
1991 2
1994 2
1995 1
1996 1
1998 2
1999 1
2000 2
2001 1
2003 1
2007 1
2008 2
2010 1
2011 2
2012 4
2013 2
2014 2
2015 4
2016 4
2017 3
2018 6
2019 3
2020 11
2021 9
2022 6
2023 8
2024 26

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

110 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Paz-Ares L, et al. Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4. Lancet. 2019. PMID: 31590988 Clinical Trial.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Goldman JW, et al. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4. Lancet Oncol. 2021. PMID: 33285097 Clinical Trial.
Inflammatory signaling pathways in Alzheimer's disease: Mechanistic insights and possible therapeutic interventions.
Almutary AG, Begum MY, Kyada AK, Gupta S, Jyothi SR, Chaudhary K, Sharma S, Sinha A, Abomughaid MM, Imran M, Lakhanpal S, Babalghith AO, Abu-Seer EA, Avinash D, Alzahrani HA, Alhindi AA, Iqbal D, Kumar S, Jha NK, Alghamdi S. Almutary AG, et al. Among authors: lakhanpal s. Ageing Res Rev. 2024 Oct 16;104:102548. doi: 10.1016/j.arr.2024.102548. Online ahead of print. Ageing Res Rev. 2024. PMID: 39419399 Review.
Epidemiological shifts: the emergence of malaria in America.
Bansal V, Munjal J, Lakhanpal S, Gupta V, Garg A, Munjal RS, Jain R. Bansal V, et al. Among authors: lakhanpal s. Proc (Bayl Univ Med Cent). 2023 Sep 14;36(6):745-750. doi: 10.1080/08998280.2023.2255514. eCollection 2023. Proc (Bayl Univ Med Cent). 2023. PMID: 37829240 Free PMC article. Review.
Overcoming challenges in the design of drug delivery systems targeting the central nervous system.
Almutary AG, Chauhan P, Baldaniya L, Menon SV, Kumar MR, Chaturvedi B, Sharma N, Chauhan AS, Abomughaid MM, M D, Paiva-Santos AC, Lakhanpal S, Jha NK. Almutary AG, et al. Among authors: lakhanpal s. Nanomedicine (Lond). 2024 Nov 20:1-4. doi: 10.1080/17435889.2024.2421157. Online ahead of print. Nanomedicine (Lond). 2024. PMID: 39564781 No abstract available.
110 results